Vasoactive intestinal peptide VIP is a 28-amino acid neuropeptide that regulates inflammation, immune tolerance, circadian rhythms, and endocrine signaling. This guide explains how VIP works, why it is used as a final-stage intervention in Chronic Inflammatory Response Syndrome CIRS , and what…
Vasoactive intestinal peptide, commonly abbreviated as VIP, is a naturally occurring signaling molecule with broad effects on the immune system, nervous system, and endocrine system. It is often described as a master regulator of inflammation because it helps shift the body from a pro-inflammatory state toward a regulatory, healing state. In clinical settings, VIP has drawn particular attention as a treatment for Chronic Inflammatory Response Syndrome, or CIRS, a condition that can develop after prolonged exposure to water-damaged buildings and mold-related biotoxins.
For people with CIRS, daily life can involve brain fog, overwhelming fatigue, joint aches, and slowed thinking. The underlying problem is not simply the mold itself. It is that the immune system becomes stuck in an activated state and cannot turn itself off. This leads to chronic inflammation that affects multiple organ systems. In the majority of CIRS patients, research and clinical experience have identified low VIP levels as a central feature of the disease. Replacing VIP through intranasal administration has become a key final step in a structured treatment protocol.
This resource explains what VIP is, how it functions in the body, why it matters in CIRS, and what evidence exists for its use. It also covers the limitations of current research and the safety considerations that patients and clinicians should keep in mind.
VIP is a peptide made up of 28 amino acids. It was first discovered in 1970, when researchers isolated it from pig intestines. That is why the word “intestinal” appears in its name, even though we now know that VIP is produced throughout the body. It is found in the gut, lungs, pancreas, and a critical brain region called the suprachiasmatic nuclei, which acts as the body’s master clock for circadian rhythms.
VIP functions as a neuroendocrine hormone, a neurotransmitter, and a regulator of cytokine activity all at once. It is one of the most versatile signaling molecules in human physiology. Its receptors are distributed across nearly every organ system, which helps explain why VIP can influence so many different processes, including immune function, blood vessel tone, hormone release, sleep, and inflammation.
A useful way to think about VIP is as the immune system’s off switch. When the immune system mounts a response to a threat, it needs a way to stand down once the threat is gone. VIP is part of that braking system. It promotes regulatory T cells that help prevent autoimmune attacks, protects neurons from inflammatory damage, maintains the blood-brain barrier, and helps regulate circadian rhythms that control hormone release. When VIP levels are adequate, the immune system can return to a balanced state after an inflammatory challenge. When VIP levels drop, the immune system may stay active indefinitely, causing the body to attack its own tissues and remain in a state of chronic inflammation.
Chronic Inflammatory Response Syndrome is a complex illness that occurs in genetically susceptible people after exposure to biotoxins, including toxins produced by mold in water-damaged buildings. The term was popularized by Dr. Ritchie Shoemaker, a physician who developed a multi-step treatment protocol for the condition. CIRS is not caused by an active infection in the traditional sense. Instead, it involves an abnormal immune response to biotoxins that the body cannot properly recognize or clear.
The symptoms of CIRS can be wide-ranging. Many patients report brain fog, fatigue, muscle aches, joint pain, headaches, shortness of breath, and digestive problems. The severity of symptoms can vary from day to day, and exposure to a contaminated building can trigger a rapid onset of symptoms. The underlying mechanism involves persistent activation of the immune system and ongoing inflammation that affects multiple systems, including the brain, endocrine glands, and blood vessels.
In CIRS, the immune system appears to lose its ability to regulate itself. Instead of resolving after the threat is removed, the inflammatory response continues. Over time, this can lead to measurable changes in the body, including elevated inflammatory markers, hormonal dysregulation, and even structural changes in the brain.
One of the most consistent laboratory findings in CIRS patients is low VIP. Clinical observations have suggested that approximately 91% of CIRS patients have abnormally low VIP levels. This is significant because VIP normally provides a counterbalance to inflammation. Without enough VIP, the immune system lacks a critical signal to stand down.
Low VIP contributes to several features of CIRS. The immune system remains activated, leading to chronic inflammation. Brain tissue may shrink over time, a finding that shows up on specialized MRI imaging. Hormones become dysregulated because the master clock in the brain, which depends on VIP, is not functioning properly. Sleep architecture collapses, and the body’s stress response systems become unbalanced.
Dr. Shoemaker identified low VIP as one of the most consistent findings in mold illness patients. He also demonstrated, through clinical use and published research, that replacing VIP through nasal spray administration could reverse damage that other interventions did not seem to touch. This is why VIP is described as the final step in the Shoemaker Protocol. It addresses a deficiency that cannot be corrected by other steps alone.
VIP exerts its effects by binding to specific receptors on the surface of cells. The two main receptor types are called VPAC1 and VPAC2. These receptors are found throughout the nervous system, on immune cells, in the gut, and in the respiratory tract. When VIP binds to these receptors, it triggers intracellular signaling cascades that change how immune cells behave.
One of the most important effects of VIP is its ability to shift the balance of cytokines. Cytokines are small signaling proteins that coordinate immune responses. Some cytokines promote inflammation, while others suppress it. VIP decreases pro-inflammatory cytokines including tumor necrosis factor-alpha, or TNF-alpha, and interleukins IL-6 and IL-12. At the same time, it increases anti-inflammatory cytokines such as IL-10.
This is not simply symptom suppression. Rather, it represents a rebalancing of immune function at the cellular level. Instead of blocking inflammation entirely, VIP helps restore the immune system’s natural ability to limit inflammation once the threat has passed.
VIP also has a direct effect on regulatory T cells, specifically CD4+CD25+ regulatory T cells. These cells act as peacekeepers for the immune system. They recognize when an immune response has become excessive and send signals that cause other immune cells to stop attacking. In chronic inflammatory conditions, this regulatory brake is often weakened or lost.
Studies have shown that VIP can increase regulatory T cell populations in the body. This effect has been observed in vivo, meaning in living organisms, and it appears to promote sustained immune tolerance rather than temporary suppression. This may explain why the benefits of VIP treatment can persist over time and do not necessarily require ever-increasing doses.
Research published by Dr. Shoemaker and colleagues demonstrated that VIP treatment reduced elevated levels of several inflammatory markers in CIRS patients. These markers include matrix metalloproteinase-9, or MMP-9, transforming growth factor-beta1, or TGF-beta1, and complement component C4a. In many CIRS patients, these markers remain elevated despite other treatments. VIP was able to lower them in patients who had been refractory to other therapies.
MMP-9 is an enzyme involved in tissue remodeling and inflammation. Elevated levels can indicate ongoing inflammatory activity, and MMP-9 is also relevant to blood-brain barrier integrity. TGF-beta1 is a multifunctional cytokine that plays a role in immune regulation and tissue repair, but abnormal elevations can be associated with chronic inflammation and fibrosis. C4a is a complement protein that is often elevated in CIRS patients and is used as a marker in the Shoemaker Protocol.
The fact that VIP normalized these markers in treatment-resistant patients is a notable finding. It suggests that VIP is addressing a distinct mechanism that other interventions do not target.
VIP is a peptide, which means it would be broken down by digestive enzymes if taken orally. To reach the central nervous system, it requires a different route of administration. Intranasal delivery has become the standard approach in clinical practice. The nasal mucosa sits adjacent to the olfactory bulb, which connects directly to the brain.
This anatomical pathway provides a direct route from the nose to the brain. VIP can reach the hypothalamus and other brain structures without needing to pass through the systemic circulation first. Interestingly, the same pathway that allows biotoxins to enter the brain during mold exposure can also be used therapeutically to deliver VIP where it is needed most.
Intranasal VIP administration also avoids the problem of digestion by stomach acid and intestinal enzymes. This makes it a practical and effective delivery method for a peptide that would otherwise be useless if swallowed.
VIP is produced in the suprachiasmatic nuclei of the hypothalamus, which is the master clock that controls circadian rhythms and hormone release. When VIP levels are low, the entire hypothalamic-pituitary axis can become dysregulated. This is a major reason why CIRS patients often experience multiple hormonal problems at once.
Clinical experience has shown that VIP treatment can help normalize several endocrine relationships that are disrupted in CIRS. These include the relationship between adrenocorticotropic hormone, or ACTH, and cortisol, the balance between antidiuretic hormone, or ADH, and osmolality, and the levels of sex hormones such as estradiol and testosterone. By restoring the central command structure in the brain, VIP helps bring the endocrine system back into balance.
This broad effect on hormone regulation is particularly important because many CIRS patients have symptoms that resemble adrenal fatigue, thyroid dysfunction, or sex hormone imbalance. Treating those hormones individually may not work if the central regulator is still malfunctioning. VIP targets the root of the problem.
VIP has been used in the treatment of CIRS since 2008. According to clinical data and real-world reports, more than 10,000 patients have been treated, and over 7,000 prescriptions have been filled by more than 314 physicians. This represents one of the largest real-world databases for any peptide therapy used in this context.
While real-world experience is extensive, published studies are relatively small. They are also largely observational or use patients as their own controls rather than comparing against a placebo group. This is important context for interpreting the strength of the evidence. The findings so far are encouraging, but they are not equivalent to large randomized controlled trials.
A foundational study published in the journal Health in 2013 followed 20 patients with refractory CIRS who used VIP nasal spray for at least 18 months. These were patients who had failed other interventions. All 20 patients reported an improvement in quality of life, which is a striking result.
Inflammatory markers including C4a, MMP-9, and TGF-beta1 normalized during treatment. Hormonal parameters including estradiol, testosterone, and cortisol returned to control ranges. Vascular endothelial growth factor, or VEGF, which had been suppressed in these patients, also normalized. Importantly, these improvements were durable. They persisted throughout the 18-month follow-up period, and patients did not require dose escalation over time.
The lack of a placebo control group and the small sample size mean that these results should be interpreted with caution. However, the durability of the response and the normalization of multiple objective markers provide meaningful evidence that VIP was having a biological effect.
A 2017 study published in Internal Medicine Review examined the effects of VIP on brain structure using before-and-after MRI imaging. Patients served as their own controls. NeuroQuant analysis, an automated tool that measures brain volumes, was used to compare grey matter volumes before VIP treatment and after.
The results showed restoration of grey matter volume in multiple brain nuclei. This suggests that brain shrinkage caused by chronic inflammation can partly reverse with VIP treatment. The idea that grey matter volume can increase after treatment is remarkable, and it has implications beyond CIRS for neurodegenerative conditions in general.
Again, this study was not a randomized controlled trial. It used patients as their own controls, which is a common approach when placebo use is difficult or unethical. Still, the MRI findings are objective and difficult to explain purely by placebo effects.
Another line of evidence comes from RNA sequencing studies published in Medical Research Archives. These studies examined gene expression changes in CIRS patients treated with VIP. The analysis revealed shifts in metabolic state and innate immune function that correlated with clinical healing.
VIP treatment normalized gene expression patterns that had been dysregulated by chronic inflammation. The molecular hypometabolism that is characteristic of CIRS, meaning reduced energy production at the cellular level, appeared to reverse at the transcriptomic level. This provides mechanistic support for the clinical improvements observed in patients.
These findings are valuable because they help explain how a single peptide can have such broad effects. By restoring normal gene expression patterns, VIP may be resetting multiple downstream pathways at once.
The Shoemaker Protocol is a structured, multi-step treatment approach for CIRS. It typically begins with removal from exposure to water-damaged buildings. Other steps involve addressing nasal infections such as MARCoNS, lowering elevated inflammatory markers, and managing hormonal dysregulation. VIP is generally introduced late in the protocol, after these prerequisite steps have been completed.
VIP is considered the final step because it corrects a deficiency that other interventions cannot address. Even after removing the patient from the offending environment and treating secondary issues, immune dysregulation and hormonal imbalances may persist. VIP is used to reset the regulatory systems that remain stuck.
The typical timeline for VIP treatment is one to three months for initial biomarker improvements and six to twelve months for full protocol completion. Patients are usually evaluated with follow-up blood work and other testing to monitor their response.
VIP treatment is not appropriate for everyone with CIRS. It is not meant for patients who are still being exposed to water-damaged buildings. Continued exposure can undermine treatment and keep the immune system activated. Patients with an active MARCoNS infection, which is a type of antibiotic-resistant staph infection in the nasal passages, are generally not candidates until that infection has been treated. Anyone who has not completed the prerequisite steps in the Shoemaker Protocol should not begin VIP therapy prematurely.
These exclusion criteria are important because they help ensure that VIP is used in the right context. Using VIP too early, or while exposure and secondary infections remain unresolved, may produce poor results.
According to over 15 years of clinical use, VIP nasal spray appears to have an excellent safety profile. No serious adverse effects have been reported in the published studies discussed here. Patients have used VIP for 18 months or longer, and the treatment appears to be well tolerated.
However, there are important limitations to the current safety data. The published studies are small, and there are no large, long-term placebo-controlled trials to date. As with any peptide therapy, the risk of unknown long-term effects cannot be completely ruled out. Patients considering VIP should be monitored by a clinician experienced with CIRS and familiar with the Shoemaker Protocol.
It is also worth noting that VIP has not been approved by regulatory agencies such as the FDA for the treatment of CIRS. In practice, VIP nasal spray is often prescribed off-label or provided through compounding pharmacies. This means that the quality, purity, and dosing of products can vary. Patients should seek care from providers who follow established protocols and use reliable sources for compounded peptides.
The current evidence supports the conclusion that VIP nasal spray can reduce inflammatory markers, improve quality of life, normalize certain hormones, and possibly restore grey matter volume in CIRS patients who have completed the prior steps of the Shoemaker Protocol. The evidence is strongest from small observational studies and real-world clinical experience, and it is supported by plausible biological mechanisms.
What the evidence does not support is the use of VIP as a standalone treatment for CIRS or as a general-purpose anti-inflammatory supplement. VIP is not a cure for mold illness, and it does not remove the need to address ongoing exposure. It is also not a first-line treatment for people who have not completed the earlier steps of the protocol.
There is also no high-quality randomized controlled trial evidence establishing the efficacy of VIP in CIRS. The existing studies are small, unblinded, and lack placebo control groups. This does not mean the findings are invalid, but it does mean they should be considered preliminary. Larger, more rigorous studies would be needed to confirm the results and to define optimal dosing, treatment duration, and patient selection.
Several important questions remain about VIP therapy. What is the ideal dose and dosing schedule? How long should patients continue treatment? Are there biomarkers that can predict which patients will respond best? Can VIP be used in other chronic inflammatory or neurodegenerative conditions? These questions require further research.
The finding that VIP may restore grey matter volume in the brain is particularly intriguing. If confirmed, it could have implications for conditions involving brain atrophy, including multiple sclerosis, chronic traumatic encephalopathy, and certain forms of dementia. However, these possibilities are speculative at this point and have not been tested in rigorous clinical trials.
VIP is a 28-amino acid neuropeptide discovered in 1970 and produced in the gut, lungs, pancreas, and suprachiasmatic nuclei of the brain. It regulates inflammation, immune tolerance, circadian rhythms, and endocrine function. Low VIP levels are present in approximately 91% of CIRS patients and are thought to contribute to persistent immune activation. VIP binds VPAC1 and VPAC2 receptors to decrease pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-12, while increasing anti-inflammatory IL-10. It also promotes CD4+CD25+ regulatory T cells, helping restore immune…